Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
2022 · Nature Medicine · 325 citations
https://doi.org/10.1038/s41591-022-01829-9
K
Katelyn T. Byrne
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
196
Papers
6.8K
Citations
27
h-index
31
i10-index
Katelyn T. Byrne is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Pancreatic and Hepatic Oncology Research & CAR-T cell therapy research. The author has an h-index of 27, co-authored 167 publications.
ORCID: 0000-0002-2459-9041Papers by this author
worksTumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
2019 · Journal of Clinical Investigation · 165 citations
https://doi.org/10.1172/jci127755
Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
2021 · Nature Communications · 149 citations
https://doi.org/10.1038/s41467-021-23832-3
Supplementary Table S1 from Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer
2024 · 1 citations
https://doi.org/10.1158/2326-6066.25736192.v1
Supplementary Figure 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
2024 · 0 citations
https://doi.org/10.1158/1078-0432.25112195
Supplementary Figure 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
2024 · 0 citations
https://doi.org/10.1158/1078-0432.25112192
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat